Evaluation of chemicals as inhibitors of trout cytochrome P450s

Toxicology and Applied Pharmacology

Volumn 148, Issue 2, 1998, Pages 237-244

  Miranda, C L ^a   Henderson, M C ^a   Buhler, D R ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FISH; LIVER MICROSOME; MAMMAL; NONHUMAN; RAINBOW TROUT; TOXICITY TESTING; TROUT; XENOBIOTIC METABOLISM;

ANIMALIA; MAMMALIA; ONCORHYNCHUS MYKISS; SALMONIDAE;

EID: 0032005776     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8341     Document Type: Article

References (52)

1. Bend J. R., Pohl R. J., Fouts J. R. Further studies of the microsomal mixed-function oxidase system of the little skate,Raja erinacea, Bull. Mt. Desert Isl. Biol. Lab. 13:1973;9-11.
2. Bornheim L. M., Underwood M. C., Caldera P., Rettie A. E., Trager W. F., Wrighton S. A., Correia M. A. Inactivation of multiple hepatic cytochrome P-450 isozymes in rats by allylisopropylacetamide: Mechanistic implications. Mol. Pharmacol. 32:1987;299-308.
3. Buhler D. R., Miranda C. L., Deinzer M. L., Griffin D. A., Henderson M. C. The regiospecific hydroxylation of lauric acid by rainbow trout (Oncorhynchus mykiss. Drug Metab. Dispos. 25:1997;1176-1183.
4. Buhler D. R., Yang Y.-H., Dreher T. W., Miranda C. L., Wang J.-L. Cloning and sequencing of the major rainbow trout constitutive cytochrome P450 (CYP2K1): Identification of a new cytochrome P450 gene subfamily and its expression in mature rainbow trout liver and trunk kidney. Arch. Biochem. Biophys. 312:1994;45-51.
5. Butler A. M., Murray M. Inhibition and inactivation of constitutive cytochrome P450 in rat liver by parathion. Mol. Pharmacol. 43:1993;902-908.
6. CaJacob C. A., Chan W. K., Shephard E., Ortiz de Montellano P. R. The catalytic site of rat hepatic lauric acid ω-hydroxylase. Protein versus heme alkylation in the ω-hydroxylation of acetylenic fatty acids. J. Biol. Chem. 263:1988;18640-18649.
7. Chang T. K. H., Gonzalez F. J., Waxman D. J. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human P450. Arch. Biochem. Biophys. 311:1994;437-442.
8. Chou M. W., Yang S. K. Combined reversed-phase and normal-phase high-performance liquid chromatography in the purification and identification of 7,12-dimethylbenz[a. J. Chromatogr. 185:1979;635-654.
9. Correia M. A. Rat and human liver cytochrome P450: Substrate and inhibitor specificities and functional markers. Cytochrome P450: Structure, Mechanism and Biochemistry. 1995;Plenum Press, New York. p. 607-627.
10. DePierre J. W., Johannesen K. A. M., Moron M. S., Seidegard J. Radioactive assay of aryl hydrocarbon hydroxylase monooxygenase and epoxide hydrolase. Methods Enzymol. 52C:1978;412-418.
11. Falckh P. H. J., Wu Q. K., Ahokas J. P. A cytochrome P450 expressed in rainbow trout (Oncorhynchus mykiss. Biochem. Biophys. Res. Commun. 236:1997;302-305.
12. Franklin M. R. Methylenedioxyphenyl insecticide synergists as potential human health hazards. Environ. Health Persp. 14:1976;29-37.
13. Franklin M. R. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol. 206:1991;559-573.
14. Giera D. D., van Lier R. B. L. A convenient method for the determination of hepatic lauric acid ω-oxidation based on solvent partition. Fundam. Appl. Pharmacol. 16:1991;348-355.
15. Guengerich F. P. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol. Pharmacol. 33:1988;500-508.
16. Guengerich F. P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3:1990;363-371.
17. Guengerich F. P., Kim D. H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4:1991;168-179.
18. Halpert J. R. Structural basis of selective cytochrome P450 inhibition. Annu. Rev. Pharmacol. Toxicol. 35:1995;29-53.
19. Halpert J. R., Guengerich F. P., Bend J. R., Correia M. A. Selective inhibitors of cytochrome P450. Toxicol. Appl. Pharmacol. 125:1994;163-175.
20. Heilmann L. J., Sheen Y-Y., Bigelow S. W., Nebert D. W. Trout P450IA1: cDNA and deduced protein sequence, expression in liver, and evolutionary significance. DNA. 7:1988;379-387.
21. Henderson M. C., Zhao X., Miranda C. L., Buhler D. R. Differential effects of β-naphthoflavone (BNF) and isosafrole (ISF) on thein vitro. The Toxicologist. 12:1992;393.
22. Lee S.-J., Yang Y.-H., Wang J.-L., Miranda C. L., Cok I., Lech J. J., Buhler D. R. Cloning, sequencing and tissue expression of the first CYP3A form from fish (CYP3A27) in rainbow trout. FASEB J. 11:1997;A824.
23. Lemaire P., Livingstone D. R. Inhibition studies on the involvement of flavoprotein reductases in menadione- and nitrofurantoin-stimulated oxyradical production by hepatic microsomes of flounder (Platichthys flesus. J. Biochem. Toxicol. 9:1994;87-95.
24. Lemaire P., Lafaurie M., Weissbart D., Durst F., Pflieger, Mioskowski C., Salaun J.-P. Subterminal hydroxylation of lauric acid by microsomes from marine fish. Lipids. 27:1992;187-191.
25. Little P. J., James M. O., Bend J. R., Ryan A. J. Imidazole derivatives as inhibitors of cytochrome P-450-dependent oxidation and activators of epoxide hydrolase in hepatic microsomes from a marine fish. Biochem. Pharmacol. 30:1981;2876-2880.
26. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
27. Mansuy D., Beaune P., Cresteil T., Bacot C., Chottard J.-C., Gans P. Formation of complexes between microsomal cytochrome P-450-Fe(II) and nitrosoarenes obtained by oxidation of arylhydroxylamines or reduction of nitroarenes in situ. Eur. J. Biochem. 86:1978;573-579.
28. Miranda C. L., Henderson M. C., Williams D. E., Buhler D. R. In vitro metabolism of 7,12-dimethylbenz[a. Toxicol. Appl. Pharmacol. 142:1997;123-132.
29. Miranda C. L., Wang J.-L., Henderson M. C., Buhler D. R. Purification and characterization of hepatic steroid hydroxylases from untreated rainbow trout. Arch. Biochem. Biophys. 268:1989;227-238.
30. Miranda C. L., Wang J.-L., Henderson M. C., Zhao X., Guengerich F. P., Buhler D. R. Comparison of rainbow trout and mammalian cytochrome P450 enzymes: Evidence for structural similarity between trout P450 LMC5 and human P450IIIA4. Biochem. Biophys. Res. Commun. 176:1991;558-563.
31. Murray M. Complexation of cytochrome P-450 isozymes in hepatic microsomes from SKF 525-A-induced rats. Arch. Biochem. Biophys. 262:1988;381-388.
32. Murray M., Butler A. M. Identification of a reversible component in thein vitro. J. Pharmacol. Exp. Ther. 272:1995;639-644.
33. Murray M., Reidy G. F. In vitro. Drug Metab. Dispos. 17:1989;449-454.
34. Murray M., Reidy G. F. Selectivity in the inhibition of mammalian P-450 by chemical agents. Pharmacol. Rev. 42:1990;85-101.
35. Nesnow S., Fahl W. E., Jefcoate C. R. An improved radiochemical assay of benzo[a. Anal. Biochem. 80:1977;258-266.
36. Newton D. J., Wang R. W., Lu A. Y. H. Cytochrome P450 inhibitors. Evaluation of specificities in thein vitro. Drug Metab. Dispos. 23:1995;154-158.
37. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239:1964;2370-2378.
38. Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F. J., Tsutsu M. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation ofin vitro. Xenobiotica. 26:1996;681-693.
39. Ortiz de Montellano P. R., Correia M. A. Inhibition of cytochrome P450 enzymes. Ortiz de Montellano P. R. Cytochrome P450: Structure, Mechanism and Biochemistry. 1995;305-364 Plenum Press, New York.
40. Ortiz de Montellano P. R., Reich N. O. Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. J. Biol. Chem. 259:1984;4136-4141.
41. Ortiz de Montellano P. R., Reich N. O. Inhibition of cytochrome P-450 enzymes. Ortiz de Montellano P. R. Cytochrome P-450. Structure, Mechanism, and Biochemistry. 1986;273-314 Plenum Press, New York.
42. Ortiz de Montellano P. R., Mico B. A., Mathews J. M., Kunze K. L., Miwa G. T., Lu A. Y. H. Selective inactivation of cytochrome P-450 isozymes by suicide substrates. Arch. Biochem. Biophys. 210:1981;717-728.
43. ++. Am. J. Physiol. 266:1994;F497-505.
44. Roos P. H., Golub-Ciosk B., Kallweit P., Kauczinski D., Hanstein W. G. Formation of ligand and metabolite complexes as a means for selective quantitation of cytochrome P450 isozymes. Biochem. Pharmacol. 45:1993;2239-2250.
45. Shou M., Grogan J., Mancewicz J. A., Krausz K. W., Gonzalez F. J., Gelboin H. V., Korzekwa K. R. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry. 33:1994;6450-6455.
46. Stegeman J. J., Hahn M. E. Molecular, biochemical and cellular perspectives. Malins D. C., Ostrander G. K. Aquatic Toxicology. 1994;87-206 Lewis Publishers, Boca Raton.
47. 1. Comp. Biochem. Physiol. 110C:1995;273-280.
48. Underwood M. C., Cashman J. R., Correia M. A. Specifically designed thiosteroids as active-site-directed probes for functional dissection of rat liver cytochrome P450 3A isozymes. Chem. Res. Toxicol. 5:1992;42-53.
49. Watson D. E., Menard L., Stegeman J. J., Di Giulio R. T. Aminoanthracene is a mechanism-based inactivator of CYP1A in channel catfish hepatic tissue. Toxicol. Appl. Pharmacol. 135:1995;208-215.
50. 11. Cancer Res. 43:1983;4752-4756.
51. Williams D. E., Buhler D. R. Benzo[a. Biochem. Pharmacol. 33:1984;3743-3753.
52. Williams D. E., Okita R. T., Buhler D. R., Masters B. S. S. Regiospecific hydroxylation of lauric acid at the (ω-1) position by hepatic and kidney microsomal cytochromes P-450 from rainbow trout. Arch. Biochem. Biophys. 231:1984;503-510.